|D012877||Skin Manifestations NIH||1.00|
There is one clinical trial.
This is a case series of patients with COVID-19 admitted to the northeast Brazil region, in a referenced hospital for COVID-19, during the 2020 COVID-19 pandemic. Data will be collected prospectively and retrospectively. The main objective is to describe the characteristics of critically ill patients with COVID-19 and their clinical outcomes, and to identify risk factors associated with survival, to guide the strategy to mitigate the epidemic, both within each hospital and ICU and in public health management.
Description: the proportion of patients who survive to ICU dischargeMeasure: ICU outcome Time: up to 60 days
Description: the proportion of patients who survive to hospitalizationMeasure: Hospital outcome Time: up to 90 days
Description: Mechanical ventilation timeMeasure: Mechanical ventilation Time: up to 60 days
Description: percentage of patients who developed complications during the hospitalization, both at ICU and during total hospitalization.Measure: Hospital complications Time: up to 90 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports